Dr. Monika Joshi, MD

Dr. Joshi practices at Penn State Health Milton S. Hershey Medical Center in Hershey, Pennsylvania, part of Penn State.

Dr. Joshi's NPI, 1265626303, was assigned on August 31, 2007. Dr. Joshi holds Pennsylvania license MD440567.

Dr. Joshi's primary practice is Penn State Health Milton S. Hershey Medical Center, at 500 University Drive, Hershey, PA 17033 in Dauphin County. The practice phone is (717) 531-8521.

Dr. Joshi's primary practice is Penn State Health Milton S. Hershey Medical Center in Hershey, Pennsylvania, part of Penn State. Dr. Joshi is also affiliated with UPMC Harrisburg. The medical group on file is Penn State Health Milton S. Hershey Medical Center. Dmand AI also links Dr. Joshi to 3 more hospitals and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Joshi practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Joshi's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Joshi is licensed in Pennsylvania.

CMS data shows 388 Medicare services from Dr. Joshi across 3 procedure codes in 2024, all of them office visits, for 133 Medicare patients. Medicare paid $36,344 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 133 Medicare patients who saw Dr. Joshi in 2024. The largest group is 65 to 74, with 65 patients. 75% of them have cancer, and 75% have high blood pressure. 8% are also on Medicaid. Their average risk score is 2.38, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Joshi's median patient age at 74, with 12% women.

In 2024, Dr. Joshi wrote 1,495 Medicare Part D claims for 123 patients. 75% of them were for generic drugs. CMS names the drug for 1,341 of them, across 30 drugs with 11 or more claims each, at $6,382,292 in total drug cost. In 2023, CMS named 1,274 claims across 29 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 79 out of 100 for Dr. Joshi for performance year 2024, reported as part of a group. Dr. Joshi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Joshi as offering telehealth.

Dmand AI links 76 papers to Dr. Joshi, published from 2011 to 2025. 2022 was the busiest year, with 12. The most frequent topics are Urinary Bladder Neoplasms, Carcinoma, Transitional Cell and Immunotherapy. Dr. Joshi has published most often in Clin Genitourin Cancer. Dr. Joshi's most frequent co-authors are Joseph J. Drabick, MD, Petros Grivas, MD and Sheldon Holder, MD.

Dmand AI links Dr. Joshi to 10 clinical trials, 4 of them phase 3 studies. 8 are still active or recruiting. Conditions studied include Carcinoma, Renal Cell, Urinary Bladder Neoplasms and Kidney Neoplasms. National Cancer Institute (NCI) sponsors the most, 5.

CMS Open Payments shows 39 general payments to Dr. Joshi from 12 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 88% of the total. Sanofi and Genzyme US Companies paid the most, $12,662. It also lists 1 research payment totaling $35 in 2016.